Zobrazeno 1 - 10
of 53
pro vyhledávání: '"paliperidone palmitate 3-monthly"'
Autor:
García-Carmona JA, Pappa S
Publikováno v:
Drug, Healthcare and Patient Safety, Vol Volume 15, Pp 113-123 (2023)
Juan Antonio García-Carmona,1– 3 Sofia Pappa4,5 1Department of Neurology, Santa Lucia University Hospital, Cartagena, Murcia, Spain; 2Unit of Acute Psychiatry, Reina Sofía University Hospital, Murcia, Spain; 3Group of Clinical and Experimental Ph
Externí odkaz:
https://doaj.org/article/cd714793108946a89db86905337f077a
Publikováno v:
Patient Preference and Adherence, Vol Volume 16, Pp 615-624 (2022)
S Kor Spoelstra,1,2 Jojanneke Bruins,2 Leonie Bais,2 Paul Seerden,3 Stynke Castelein,2,4 Henderikus Knegtering2,5 1Addiction Care North Netherlands, Groningen, the Netherlands; 2Lentis Psychiatric Institute, Groningen, the Netherlands; 3GGZ Friesland
Externí odkaz:
https://doaj.org/article/22d3e9abdc254a3dab9bdf14453c96ae
Autor:
Katalin Pungor, Pedro Sanchez, Sofia Pappa, Jerome Attal, Karolina Leopold, Geertje Steegen, Antonio Vita, Carol Marsella, Caroline Verrijcken, Marjolein Lahaye, Annette Wooller
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background To understand the implications of switching from paliperidone palmitate 1-monthly (PP1M) to paliperidone palmitate 3-monthly (PP3M) treatment of schizophrenia from the perspective of four key stakeholders: patients, physicians, nu
Externí odkaz:
https://doaj.org/article/57e63c84a17d410db14ac91b3e7237cf
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol Volume 16, Pp 3197-3208 (2020)
Martin Lambert,1 Pedro Sanchez,2,3 Paul Bergmans,4 Srihari Gopal,5 Maju Mathews,6 Annette Wooller,7 Katalin Pungor8 1Centre for Psychosis and Integrated Care, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Ha
Externí odkaz:
https://doaj.org/article/00d4667034aa46aead45bacd995c1fdc
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol Volume 15, Pp 1365-1379 (2019)
Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Ne
Externí odkaz:
https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc
Autor:
Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Publikováno v:
Comprehensive Psychiatry, Vol 107, Iss , Pp 152233- (2021)
Rationale: Reducing the frequency of long-acting injectable antipsychotic medication may reduce carer burden. Objectives: To evaluate the impact of reduced frequency of long-acting injectable antipsychotic medication on carer burden in stable patient
Externí odkaz:
https://doaj.org/article/51ab9250a21847269b9ad3fa8a1bb76a
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2807-2816 (2018)
Maju Mathews,1 Isaac Nuamah,1 Adam J Savitz,1 David W Hough,1 Dean Najarian,2 Edward Kim,2 Srihari Gopal1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Janssen Scientific Affairs, Titusville, LLC, NJ, USA Objective: The aim of this st
Externí odkaz:
https://doaj.org/article/65792ee977724b2386b52b08d8e5f73b
Autor:
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein, Henderikus Knegtering
Publikováno v:
Patient Preference and Adherence, 16, 615-624. DOVE MEDICAL PRESS LTD
S Kor Spoelstra,1,2 Jojanneke Bruins,2 Leonie Bais,2 Paul Seerden,3 Stynke Castelein,2,4 Henderikus Knegtering2,5 1Addiction Care North Netherlands, Groningen, the Netherlands; 2Lentis Psychiatric Institute, Groningen, the Netherlands; 3GGZ Friesland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d49a2dbeaddda918360345dd7f0ba90
https://doi.org/10.2147/ppa.s349460
https://doi.org/10.2147/ppa.s349460
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Karolina Leopold, Caroline Verrijcken, Carol Marsella, Antonio Vita, Sofia Pappa, Katalin Pungor, Annette Wooller, Jerome Attal, Marjolein Lahaye, Geertje Steegen, Pedro Sánchez
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-15 (2021)
BMC Psychiatry
BMC Psychiatry
Background To understand the implications of switching from paliperidone palmitate 1-monthly (PP1M) to paliperidone palmitate 3-monthly (PP3M) treatment of schizophrenia from the perspective of four key stakeholders: patients, physicians, nurses and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaff3f876041c9d61a6007ddaa8c0968
https://doi.org/10.1186/s12888-021-03305-z
https://doi.org/10.1186/s12888-021-03305-z